PMID- 22166644
OWN - NLM
STAT- MEDLINE
DCOM- 20120425
LR  - 20151119
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 123
IP  - 24
DP  - 2010 Dec
TI  - Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes 
      mellitus.
PG  - 3640-3
AB  - BACKGROUND: The development of diabetic cardiomyopathy is multifactorial. Insulin 
      resistance (IR) and excessive activity of the renin-angiotensin system are 
      confirmed reasons for diabetic cardiomyopathy. Renin-angiotensin system (RAS) 
      inhibitors can reduce tissue Ang II levels, with beneficial effects on 
      cardiovascular function. Therefore, in type-2 diabetes mellitus (T2DM), blockade 
      of the RAS may have the function of protecting against diabetic cardiomyopathy 
      through increasing insulin sensitivity and inhibiting excessive activity of RAS. 
      However, this has not been confirmed. METHODS: The effect of valsartan, an 
      angiotensin receptor blocker (ARB), on diabetic cardiomyopathy in the presence of 
      T2DM was studied. Wistar rats with T2DM and T2DM treated with valsartan were 
      studied. Glucose infusion rates (GIR), index of IR, heart weight, the heart 
      weight-to-body weight ratio (HW/BW), myocardial apoptotic index, cardiac 
      hydroxyprolin content, and cardiac tissue collagen type I and collagen type III 
      content were measured. RESULTS: GIR in T2DM rats and T2DM rats treated with 
      valsartan decreased (P < 0.01). In T2DM rats treated with valsartan, heart 
      weight, myocardial apoptotic index, cardiac hydroxyprolin content, and cardiac 
      tissue collagen type I and collagen type III content were higher than in control 
      rats, but lower than in T2DM rats. In rats with T2DM, GIR was negatively and 
      significantly correlated with all the variables. However, in T2DM rats treated 
      with valsartan or normal control rats, none of the correlations was significant. 
      CONCLUSIONS: In the presence of T2DM, diabetic cardiomyopathy is related with IR. 
      Valsartan can not alleviate IR, but can protect against diabetic cardiomyopathy 
      and remove the correlation between IR and diabetic cardiomyopathy.
FAU - Yang, Zhong-Hua
AU  - Yang ZH
AD  - Department of Geriatrics, West China Hospital, West China Medical Hospital of 
      Sichuan University, Chengdu, Sichuan 610041, China. 417354278@qq.com
FAU - Peng, Xiao-Dong
AU  - Peng XD
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Collagen Type I)
RN  - 0 (Collagen Type III)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - HG18B9YRS7 (Valine)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Animals
MH  - Apoptosis
MH  - Collagen Type I/analysis
MH  - Collagen Type III/analysis
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Diabetic Cardiomyopathies/*prevention & control
MH  - Hydroxyproline/analysis
MH  - Insulin Resistance
MH  - Male
MH  - Myocardium/chemistry/pathology
MH  - Rats
MH  - Rats, Wistar
MH  - Tetrazoles/*therapeutic use
MH  - Valine/*analogs & derivatives/therapeutic use
MH  - Valsartan
EDAT- 2011/12/15 06:00
MHDA- 2012/04/26 06:00
CRDT- 2011/12/15 06:00
PHST- 2011/12/15 06:00 [entrez]
PHST- 2011/12/15 06:00 [pubmed]
PHST- 2012/04/26 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2010 Dec;123(24):3640-3.